Reisa A Sperling Selected Research

Cerebral Cortical Thinning

1/2020	Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease.
1/2019	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
1/2018	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
1/2017	The association between tau PET and retrospective cortical thinning in clinically normal elderly.
1/2016	Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study.
11/2014	Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum.
1/2014	Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.
11/2013	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease.
6/2011	Amyloid-β associated cortical thinning in clinically normal elderly.
3/2009	The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Reisa A Sperling Research Topics

Disease

139	Alzheimer Disease (Alzheimer's Disease) 12/2022 - 04/2005
72	Cognitive Dysfunction 12/2022 - 01/2009
41	Dementia (Dementias) 12/2022 - 03/2009
21	Atrophy 04/2022 - 10/2009
12	Disease Progression 01/2022 - 04/2005
10	Cerebral Cortical Thinning 01/2020 - 03/2009
5	Proteostasis Deficiencies 09/2021 - 01/2018
5	Tauopathies 01/2019 - 10/2016
4	Amyloid Plaque 01/2022 - 04/2014
3	Amyloidosis 10/2018 - 07/2015
2	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2022 - 01/2022
2	TDP-43 Proteinopathies 01/2020 - 01/2018
2	Type 2 Diabetes Mellitus (MODY) 01/2019 - 09/2014
2	Neurobehavioral Manifestations 01/2019 - 06/2011
2	Agnosia (Visual Agnosia) 01/2017 - 01/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Occupational Stress 01/2021
1	Primary Progressive Aphasia 01/2020
1	limbic-predominant age-related TDP-43 encephalopathy 01/2019
1	Amnesia (Dissociative Amnesia) 01/2019
1	Delirium 01/2019
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2019
1	Hippocampal Sclerosis 01/2018
1	Prodromal Symptoms 01/2018
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2018
1	Overweight 01/2016
1	Familial Cerebral Amyloid Angiopathy 01/2016
1	Anhedonia 01/2015
1	Hallucinations (Hallucination) 11/2014
1	Insulin Resistance 09/2014
1	Hyperglycemia 09/2014
1	Memory Disorders (Memory Loss) 04/2014
1	Nervous System Diseases (Neurological Disorders) 11/2012
1	Genetic Risk Score 11/2012
1	Vascular Diseases (Vascular Disease) 06/2012
1	Siderosis 07/2011
1	Edema (Dropsy) 07/2011

Drug/Important Bio-Agent (IBA)

100	Amyloid (Amyloid Fibrils)IBA 12/2022 - 03/2009
63	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2005
15	Apolipoproteins E (ApoE)IBA 04/2022 - 01/2009
13	Amyloid beta-PeptidesIBA 03/2022 - 04/2010
7	Presenilin-1IBA 12/2022 - 12/2012
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2012
7	ApolipoproteinsIBA 01/2019 - 12/2012
6	7- (6- fluoropyridin- 3- yl)- 5H- pyrido(4,3- b)indoleIBA 05/2021 - 01/2017
6	florbetapirIBA 01/2019 - 10/2012
6	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2019 - 03/2010
6	Glucose (Dextrose)FDA LinkGeneric 04/2017 - 06/2011
5	Apolipoprotein E4IBA 01/2022 - 01/2013
4	Biological ProductsIBA 01/2022 - 01/2018
3	APTIBA 10/2019 - 12/2015
2	Apolipoprotein E3IBA 01/2022 - 11/2019
2	Indicators and Reagents (Reagents)IBA 09/2021 - 11/2012
2	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2020 - 01/2018
2	tau Proteins (tau Protein)IBA 01/2019 - 08/2012
2	CholesterolIBA 01/2019 - 01/2015
2	CarbonIBA 01/2019 - 01/2018
1	CytokinesIBA 01/2022
1	Interleukin-12 (IL 12)IBA 01/2022
1	antineoplaston A10 (A 10)IBA 01/2022
1	Retinaldehyde (Retinal)IBA 01/2021
1	Pemetrexed (MTA)FDA Link 11/2020
1	oxidized low density lipoproteinIBA 01/2019
1	Cholinergic Agents (Cholinergics)IBA 01/2019
1	HDL LipoproteinsIBA 01/2019
1	Scopolamine (Hyoscine)FDA Link 01/2019
1	Triglycerides (Triacylglycerol)IBA 01/2019
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2018
1	Dopamine (Intropin)FDA LinkGeneric 02/2016
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 02/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	Peptides (Polypeptides)IBA 10/2015
1	chemotactic factor inactivatorIBA 04/2015
1	HomocysteineIBA 01/2015
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2015
1	N2- ((2S)- 2- (3,5- difluorophenyl)- 2- hydroxyethanoyl)- N1- ((7S)- 5- methyl- 6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- L- alaninamideIBA 01/2015
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2014
1	Deoxyglucose (2 Deoxy D glucose)IBA 11/2013
1	Flavin-Adenine Dinucleotide (FAD)IBA 10/2013
1	RadiopharmaceuticalsIBA 01/2013
1	Donepezil (Aricept)FDA LinkGeneric 01/2012
1	Pharmaceutical PreparationsIBA 01/2012
1	HemosiderinIBA 07/2011
1	bapineuzumabIBA 04/2010
1	Monoclonal AntibodiesIBA 04/2010

Therapy/Procedure

16	Activities of Daily Living (ADL) 01/2022 - 01/2011
9	Secondary Prevention 01/2020 - 03/2013
7	Therapeutics 01/2022 - 04/2005